Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review [0.03%]
伊匹单抗作为晚期黑色素瘤免疫治疗的单药或联合用药：批判性回顾
Omar Abdel-Rahman
Omar Abdel-Rahman
Aim: A pooled analysis of the efficacy and toxicity of combination immunotherapy versus single-agent ipilimumab in the management of advanced melanoma has been conducted. ...
Antonia Digklia,Olivier Michielin
Antonia Digklia
The past decade has witnessed impressive new developments for the treatment of melanoma. The discovery of key oncogenic driver mutations, upon which tumor establishment and progression are dependent, changed the prognosis of patients with s...
Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma [0.03%]
铜螯合剂治疗携带BRAF V600突变的黑色素瘤的理论依据
Sarah Sammons,Donita Brady,Linda Vahdat et al.
Sarah Sammons et al.
The successful targeting of oncogenic BRAFV600 represents one of the landmark breakthroughs in therapy for advanced melanoma. While the initial clinical benefit can be dramatic, resistance is common due to a number of mechanisms, including ...
Ricardo Moreno-Traspas,Igor Vujic,Martina Sanlorenzo et al.
Ricardo Moreno-Traspas et al.
Melanoma is one of the leading cancers worldwide, distinguished for its malignancy and low survival rates. Although the poor outcome could improve with an early diagnosis and a good monitoring of the disease, current melanoma biomarkers dis...
Mario Mandalà,Barbara Merelli,Daniela Massi
Mario Mandalà
The use of monoclonal antibodies that block immunologic checkpoints that would otherwise mediate the adaptive immune resistance have paved the way in cancer treatment. There is evidence that blocking the PD-1/PD-L1 axis is a strategy of ove...
Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab [0.03%]
立体放射外科手术治疗接受伊匹单抗治疗的黑色素瘤脑转移患者的效果及毒性反应
Adam C Olson,Samantha Thomas,Rosie Qin et al.
Adam C Olson et al.
Purpose: Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety. Methods: ...
Mary-Kate Malecek,June K Robinson,Karl Bilimoria et al.
Mary-Kate Malecek et al.
40 years in melanoma research: an interview with Meenhard Herlyn about his career in research and the outlook for the field [0.03%]
纪念发现黑色素瘤相关研究40周年——访谈梅纳德·赫尔伦博士及其对黑色素瘤研究的展望
Meenhard Herlyn
Meenhard Herlyn
Meenhard Herlyn speaks to Sebastian Dennis-Beron, Commissioning Editor: Dr Meenhard Herlyn is Caspar Wistar Professor for Melanoma Research and Director of the Melanoma Research Center at The Wistar Institute in Philadelphia, as well as Fou...
Pin1-FOXM1 inhibitors: a potential therapeutic for metastatic melanoma? [0.03%]
针对转移性黑色素瘤的PIN1-FOXM1抑制剂：潜在疗法？
Peter Lj de Keizer
Peter Lj de Keizer
Neoadjuvant treatment for melanoma: current challenges and future perspectives [0.03%]
黑色素瘤的新辅助治疗：当前挑战与未来展望
Yana G Najjar,John M Kirkwood
Yana G Najjar
There will be an estimated 76,100 new cases of melanoma diagnosed in 2015 and 9710 deaths. Patients with stage I/II disease have excellent outcomes, and the treatment landscape for patients with metastatic disease has been transformed by th...